RankingsPricing
  1. US-listed companies
  2. Intra-Cellular Therapies, Inc.
  3. Financials
  4. Research & development

Intra-Cellular Therapies, Inc.ITCI

Market cap
$13.4B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 2024236+31.07%
Dec 31, 2023180+33.72%
Dec 31, 2022135+51.63%
Dec 31, 202189+35.06%
Dec 31, 202066-26.19%
Dec 31, 201989-32.57%
Dec 31, 2018132+66.42%
Dec 31, 201779-15.36%
Dec 31, 201694+6.97%
Dec 31, 201588+313.25%
Dec 31, 201421-7.82%
Dec 31, 201323

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)